BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Vernalis PLC (VNLPY.PK) Release: AUY922 Abstracts Accepted for Presentation at American Society of Clinical Oncology 2012


6/1/2012 10:22:06 AM

1 June 2012 -- Vernalis plc today announces three abstracts under its Hsp90 collaboration with Novartis have been accepted for presentation at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago from 1 to 5 June.

The abstracts can be viewed on the ASCO website www.abstract.asco.org/ConfCatView_114_S.html.

AUY922 is a novel intravenous Hsp90 inhibitor for the treatment of a range of solid tumours. It was the first compound from a collaboration between Vernalis and Novartis to enter clinical testing and has completed phase I trials and is currently in a number of phase II trials. Novartis is conducting and funding future development and Vernalis will receive milestones and royalties on successful development and commercialisation.

Enquiries:

Vernalis Contacts

Ian Garland, Chief Executive Officer

+44 (0) 118 989 9360

David Mackney, Chief Financial Officer

Brunswick Group

Jon Coles

+44 (0) 20 7404 5959

Kristin Shine

Taylor Rafferty

Rob Newman

+44 (0) 20 7614 2900

Faisal Kanth

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes. Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Endo, GSK, Lundbeck, Menarini, Novartis and Servier.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->